NYS DOH Informational Message: Monoclonal Antibodies
Monoclonal antibody treatments for COVID-19 are no
longer being distributed through a state allocation system. There is no
shortage in supply of these drugs, and the U.S. Department of Health and Human
Services (HHS) has enough on hand to meet the needs of all treatment
facilities. For this reason, these therapies are now available through direct
ordering only. All
treatment sites meeting EUA requirements must now order COVID-19 mAb therapies
directly from AmerisourceBergen Corporation (ABC), the drugs' sole distributor.
The products remain free of charge to requesting sites.
HHS will continue to monitor all direct orders and
retains the capacity to resume allocation of these and future therapies if needed.
Treatment sites should review the direct ordering process guide and place orders directly with ABC at this site.
Please note that in addition to reporting
therapeutics data in HHSProtect or the National Healthcare Safety Network,
treatment sites wishing to place direct orders will be required to provide ABC
with a board of pharmacy license or physician letter of authorization, attest
to their designated class of trade, and ensure that product administration will
be conducted according to the drugs' EUAs.
Should you have any questions or concerns
regarding the direct order process for COVID-19 monoclonal antibodies, you may
contact HHS/ASPR at COVID19Therapeutics@hhs.gov or ABC at C19therapies@amerisourcebergen.com.